• Corpus ID: 6855846

GUIDEL INE FOR THE Treatment of Patients With Alzheimer ’ s Disease and Other Dementias

  title={GUIDEL INE FOR THE Treatment of Patients With Alzheimer ’ s Disease and Other Dementias},
  author={Deborah Blacker and D. M. Sc. and Barry W Rovner and Doukoure M and Teresa A. Rummans and Lon S Schneider and Pierre N. Tariot and David M. Blass and Molly T. Finnerty and Barbara S. Schneidman},
A guideline watch, summarizing significant developments in the scientific literature since publication of this guideline , may be available in the Psychiatric Practice section of the APA Web site at www.psych.org. reports no competing interests. The Executive Committee on Practice Guidelines has reviewed this guideline and found no evidence of influence from these relationships. The APA Practice Guidelines are not intended to be construed or to serve as a standard of medical care. Standards of… 


Evaluation of dementia: A systematic study of the usefulness of the American Academy of Neurology's Practice Parameters
Although imperfect, the Practice Parameters represent a first step toward improving the cost effectiveness of the dementia work-up, although at a significant difference in cost.
The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective.
Except for autosomal dominant early-onset families, genetic testing in asymptomatic individuals is unwarranted and use of APOE genetic testing as a diagnostic adjunct in patients already presenting with dementia may prove useful but it remains under investigation.
Practice parameter: Diagnosis of dementia (an evidence-based review)
D diagnostic criteria for dementia have improved since the 1994 practice parameter, and further research is needed to improve clinical definitions of dementia and its subtypes, as well as to determine the utility of various instruments of neuroimaging, biomarkers, and genetic testing in increasing diagnostic accuracy.
Effects of Respite Care on Patients With Dementia and Their Caregivers
  • A. Flint
  • Medicine, Psychology
    International Psychogeriatrics
  • 1995
There was little evidence that formal respite care has a significant effect on caregivers' burden, psychiatric status, or physical health; or on patients' cognition, function, physical health, or rate of institutionalization.
Guidelines for legal and financial counseling of Alzheimer's disease patients and their families.
The general purposes and the process of legal and financial counseling of the patient and the family in planning for the patient's long-term care are described as a guide for physicians who care for these patients and their families.
Interventions for Persons with Irreversible Dementia
Key findings include the identification of well-supported cognitive-behavioral interventions to enhance cognitive functioning and memory, and to relieve depression in the early disease stages; multiple environmental and behavioral approaches for improvement in functioning, maintenance of activities, and alleviation of behavioral symptoms in the middle disease stages.
Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review)
Screening different groups of elderly individuals in a general or specialty practice would be beneficial in detecting dementia and persons with memory impairment who were not demented were characterized in the literature as having mild cognitive impairment.
Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia.
Only behavior management therapies, specific types of caregiver and residential care staff education, and possibly cognitive stimulation appear to have lasting effectiveness for the management of dementia-associated neuropsychiatric symptoms.
Practice guideline for the treatment of patients with bipolar disorder (revision).
This guideline is more than 5 years old and has not yet been updated to Ensure that it reflects current knowledge and practice, and can no longer be assumed to be current.
Biomarkers in the Diagnosis of Alzheimer’s Disease: Are We Ready?
The potential use of biomarkers in the diagnosis of Alzheimer’s disease, in the monitoring of mild cognitive impairment, and as possible prognostic markers in normal controls at risk for dementia are focused on.